CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease

Experimental and Molecular Medicine

Volumn 48, Issue 1, 2016, Pages

  Chung, Young C ^a,b,f   Shin, Won Ho ^c   Baek, Jeong Y ^a,b   Cho, Eun J ^a,b   Baik, Hyung H ^a   Kim, Sang R ^d   Won, So Yoon ^e   Jin, Byung K ^a,b  

^a Kyung Hee University Hospital   (South Korea)

^b Kyung Hee University   (South Korea)

^c Korea Institute of Toxicology   (South Korea)

^d Kyungpook National University   (South Korea)

^e Chungbuk National University   (South Korea)

^f ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CD11B ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; CHEMOKINE; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOTHIOCYANIC ACID; MACROPHAGE AG COMPLEX 1; MYELOPEROXIDASE; NEUROTROPHIC FACTOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; BLOOD BRAIN BARRIER; CELL INFILTRATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME SYNTHESIS; EXPERIMENTAL PARKINSONISM; FLUORESCEIN ISOTHIOCYANATE LABELED ALBUMIN ASSAY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PERIPHERAL IMMUNE CELL INFILTRATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; DISEASE MODEL; IMMUNOLOGY; MACROPHAGE; PARKINSON DISEASE; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BLOOD-BRAIN BARRIER; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GLIAL FIBRILLARY ACIDIC PROTEIN; MACROPHAGES; MALE; MICE, INBRED C57BL; NEUROPROTECTION; PARKINSON DISEASE, SECONDARY; RECEPTOR, CANNABINOID, CB2; SUBSTANTIA NIGRA;

EID: 84992037112     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2015.100     Document Type: Article

References (55)

1. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116: 1744-1754
2. Appel SH. CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest 2009; 119: 13-15
3. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69
4. Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH, et al. The role of neuroinflammation on the pathogenesis of Parkinson s disease. BMB Rep 2010; 43: 225-232
5. Hwang O. Role of oxidative stress in Parkinson s disease. Exp Neurobiol 2013; 22: 11-17
6. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009; 1788: 842-857
7. Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC, et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson s disease in mice. J Neurosci 2005; 25: 6594-6600
8. Chung YC, Kim SR, Jin BK. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson s disease. J Immunol 2010; 185: 1230-1237
9. Huh SH, Chung YC, Piao Y, Jin MY, Son HJ, Yoon NS, et al. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson s disease. J Immunol 2011; 187: 960-969
10. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999; 5: 1403-1409
11. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994; 180: 147-150
12. Nagatsu T, Sawada M. Biochemistry of postmortem brains in Parkinson s disease: historical overview and future prospects. J Neural Transm Suppl 2007; 72: 113-120
13. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22: 1763-1771
14. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119: 182-192
15. Kawamoto Y, Ito H, Ayaki T, Takahashi R. Immunohistochemical localization of apoptosome-related proteins in Lewy bodies in Parkinson s disease and dementia with Lewy bodies. Brain Res 2014; 1571: 39-48
16. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-691
17. Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007; 28: 39-45
18. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006; 1071: 10-23
19. Onaivi ES. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 2006; 54: 231-246
20. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003; 23: 1398-1405
21. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 2003; 41: 161-168
22. Martin-Moreno AM, Reigada D, Ramirez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 2011; 79: 964-973
23. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904-1913
24. Ortega-Gutierrez S, Molina-Holgado E, Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005; 52: 163-168
25. Tanikawa T, Kurohane K, Imai Y. Regulatory effect of cannabinoid receptor agonist on chemokine-induced lymphocyte chemotaxis. Biol Pharm Bull 2011; 34: 1090-1093
26. Fernandez-Lopez D, Faustino J, Derugin N, Wendland M, Lizasoain I, Moro MA, et al. Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. Neuroscience 2012; 207: 307-315
27. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 2010; 24: 788-798
28. Amenta PS, Jallo JI, Tuma RF, Elliott MB. A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J Neurosci Res 2012; 90: 2293-2305
29. Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A, et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson s disease patients. Ann Neurol 2005; 57: 777-779
30. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson s disease. Eur J Neurosci 2009; 29: 2177-2186
31. Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR, et al. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 2011; 187: 6508-6517
32. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011; 60: 963-974
33. Chung YC, Kim YS, Bok E, Yune TY, Maeng S, Jin BK. MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage and neuroinflammation in an MPTP mouse model of Parkinson s disease. Mediators Inflamm 2013; 2013: 370526
34. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991; 231: 482-497
35. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005; 57: 176-179
36. Pisani V, Stefani A, Pierantozzi M, Natoli S, Stanzione P, Franciotta D, et al. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation 2012; 9: 188
37. Chao YX, He BP, Tay SS. Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson s disease. J Neuroimmunol 2009; 216: 39-50
38. Chen X, Lan X, Roche I, Liu R, Geiger JD. Caffeine protects against MPTPinduced blood-brain barrier dysfunction in mouse striatum. J Neurochem 2008; 107: 1147-1157
39. Perry VH. Innate inflammation in Parkinson s disease. Cold Spring Harb Perspect Med 2012; 2: a009373
40. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, et al. Peripheral cytokines profile in Parkinson s disease. Brain Behav Immun 2009; 23: 55-63
41. Shimoji M, Pagan F, Healton EB, Mocchetti I. CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox Res 2009; 16: 318-328
42. Panaro MA, Cianciulli A. Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson s disease. Curr Pharm Des 2012; 18: 200-208
43. Hirsch EC, Hunot S. Neuroinflammation in Parkinson s disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-397
44. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson s disease. Parkinsonism Relat Disord 2012; 18(Suppl 1): S210-S212
45. Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J, Hoglinger GU. Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol 2012; 238: 183-191
46. Episcopo FL, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration. Curr Aging Sci 2013; 6: 45-55
47. Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson s disease. Neurotherapeutics 2010; 7: 413-423
48. Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, et al. The role of glial cells in Parkinson s disease. Curr Opin Neurol 2001; 14: 483-489
49. Oki C, Watanabe Y, Yokoyama H, Shimoda T, Kato H, Araki T. Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice. Cell Mol Neurobiol 2008; 28: 417-430
50. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 2002; 83: 167-175
51. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase and bacterial killing. Blood 1998; 92: 3007-3017
52. Arnhold J, Flemmig J. Human myeloperoxidase in innate and acquired immunity. Arch Biochem Biophys 2010; 500: 92-106
53. Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis 2007; 26: 36-46
54. Rite I, Machado A, Cano J, Venero JL. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 2007; 101: 1567-1582
55. Desai BS, Monahan AJ, Carvey PM, Hendey B. Blood-brain barrier pathology in Alzheimer's and Parkinson s disease: implications for drug therapy. Cell Transplant 2007; 16: 285-299